Polaryx Therapeutics (PLYX)
Develops PLX-200 and other candidates for rare pediatric lysosomal storage disorders.
$2.02
Pre-market−0.01 (−0.49%)
At close$2.03(+2.53%)
In millions of USD, except per-share figures
| In millions | Q3 FY24Sep 2024 | Q4 FY24Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| 1 | 1 | 5 | 1 | 1 | 1 | 2 | 1 | |
| Research & development | 0 | 0 | 5 | 0 | 1 | 1 | 1 | 1 |
| 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | |
| General & administrative | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 |
| Operating income | −1 | −1 | −5 | −1 | −1 | −1 | −2 | −1 |
| 0 | 0 | 0 | 0 | 0 | −1 | −1 | 0 | |
| Other non-operating income | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 |
| Income before tax | −1 | −1 | −5 | −1 | −1 | −1 | −3 | −1 |
| Net income from continuing operations | −1 | −1 | −5 | −1 | −1 | −1 | −3 | −1 |
| Net income | −1 | −1 | −5 | −1 | −1 | −1 | −3 | −1 |
| EPS, basic | −$0.00 | −$0.00 | −$0.03 | −$0.01 | −$0.01 | −$0.03 | −$0.05 | −$0.03 |
| EPS, diluted | −$0.00 | −$0.00 | −$0.03 | −$0.01 | −$0.01 | −$0.03 | −$0.05 | −$0.03 |
| Weighted average shares, basic | 189 | 189 | 189 | 189 | 189 | 47 | 47 | 48 |
| Weighted average shares, diluted | 189 | 189 | 189 | 189 | 189 | 47 | 47 | 48 |
| EBITDA | −1 | −1 | −5 | −1 | −1 | −1 | −3 | −1 |
| EBIT | −1 | −1 | −5 | −1 | −1 | −1 | −3 | −1 |